CAS: 20327-23-5; 1-Cyclopropylpiperazine

相似化合物

139256-79-4 223556-29-4 159974-58-0

上下游产品

CAS号77278-34-3 1-CYCLOPROPYLPI... | CAS号110694-10-5 bis-(2-sulfooxy... | CAS号765-30-0 环丙胺 | CAS号77278-34-3 1-CYCLOPROPYLPI...

1-环丙基哌嗪-4-羧酸叔丁酯置于盐酸体系中,用 1,4-二氧六环 用作溶剂,化学反应 3.0H,以59.7%的收率获得1-环丙基哌嗪
参考文献:Novel Compounds
标题:Novel Compounds
摘要:提供了一个式(I)的化合物,或其药用可接受的盐.还提供了制备式1化合物的方法,以及将式1化合物用作药物和用于癌症治疗的用途.

专利信息

专利号:US-2025115551-A1
优先权日:2023-10-03
标 题:Synthesis of ras inhibitors
发明人：LI YI; MENDOZA BENJAMIN; NAGANATHAN SRIRAM; WANG ROSS; YI YI; BALLMER STEVEN G; DAVIDSON JAMES; HUANG XIAOJUN
权利人:REVOLUTION MEDICINES INC
摘要:The present invention relates to Ras inhibitors, intermediates in the synthesis thereto, and methods for preparing the Ras inhibitors and the intermediates.

专利号:FR-2967673-A1
优先权日:2010-11-24
标题:SYNTHESIS OF N-HETEROCYCLES BY REDUCTIVE ALKYLATION OF CYAN DERIVATIVES

专利号:EP-2643309-A1
优先权日:2010-11-24
标题:Synthesis of n-heterocycles by reductive alkylation of cyan derivatives

专利号:WO-2012069566-A1
优先权日:2010-11-24
标 题 :Synthesis of n-heterocycles by reductive alkylation of cyan derivatives

专利号:WO-2025076071-A2
优先权日:2023-10-03
标 题 :Synthesis of ras inhibitors

专利号:US-11325903-B2
优先权日:2016-11-30
标 题:Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
发明人：SIDDIQUI M ARSHAD; CIBLAT STEPHANE; DERY MARTIN; CONSTANTINEAU-FORGET LEA; GRAND-MAITRE CHANTAL; BRUNEAU-LATOUR NICOLAS; SHIPPS GERALD W; COOPER ALAN B; OZA VIBHA; KOSTURA MATTHEW J; LUTHER MICHAEL; LEVINE JEDD
权利人:BANTAM PHARMACEUTICAL LLC
摘要:Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R 1 , L 1 , L 2 , Q, L 3 , R 3 , L 4 , R 4 , L 5 , and R 5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.